This open-label, prospective study evaluated the effectiveness and safety of empagliflozin as add-on therapy in inadequately controlled type 2 diabetes (T2D) patients (glycated haemoglobin
| INTRODUCTION
In type 2 diabetes (T2D), there is a progressive loss of pancreatic β cell function and onset of insulin resistance. 1 Injection therapy using insulin is considered the gold standard to control T2D patients with uncontrolled glycaemia, with other injection alternatives, such as glucagon-like peptide-1 receptor agonist, being available as needed.
However, there are limitations to injection therapy in T2D patients, such as lack of compliance with the injection, increased likelihood of hypoglycaemia and difficulty in achieving target glycaemic levels, and diminished quality of life. [2] [3] [4] Orally active antidiabetic agents (OAD), including metformin, sulfonylurea, thiazolidinedione and dipeptidyl peptidase-4 (DPP4) inhibitor, are available, but T2D patients with poor glycaemic control are generally inadequately treated with a single OAD and require two or three OADs. Even with the current panoply of OADs, the control of glycaemia is still not optimal in many patients and requires additional intervention with drugs.
To meet this goal, new OADs have been developed by inhibiting the sodium-glucose co-transporter 2 (SGLT2). These drugs have a unique mechanism of action that decreases blood glucose by elevating glucosuria, independent of insulin resistance or pancreatic β cell function. SGLT2 inhibitors are now one of the recommended treatment options for combination therapy with other OADs. 5 Empagliflozin (Jardiance; Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany) is a member of the gliflozin class of highly selective SGLT2
inhibitors and has been shown, as a single agent or in dual or even triple combination therapy with other OADs or insulin, to be effective in improving blood glucose. [6] [7] [8] A recent study by our group has shown similar efficacy in improvement of glycaemic control in T2D patients using dapagliflozin, another gliflozin class member, as add-on therapy to three other OADs. 9 In this study, a prospective observational trial was conducted to determine the effectiveness and safety of empagliflozin (EMPA) as an add-on OAD, compared with insulin glargine (INS), in suboptimally controlled T2D patients who were already using three different OADs. when measuring daily fasting blood glucose. Doses of metformin and DPP4 inhibitor were fixed at before-study levels, whereas a 50% reduction in the dose of glimepiride was recommended for patients experiencing hypoglycaemia. Both groups of patients received conventional education concerening diabetes self-management, including a lifestyle modification programme from a trained nurse. All patients were followed at intervals of 12 weeks. At each visit, adherence was assessed by checking the number of remaining unused OAD pills or insulin pens.
| Effectiveness and safety assessments
The primary effectiveness outcome was mean change in HbA1c level from baseline to Week 24. Secondary effectiveness outcomes were mean changes in fasting plasma glucose (FPG), post-prandial 2-h glucose (PP2), systolic (SBP) and diastolic blood pressure (DBP), Wt, and lipid profiles from baseline to Week 24 (File S1). Safety outcomes included vital signs, laboratory test result abnormalities and reported experiences of adverse events (AEs). AEs of special interest included hypoglycaemia, genitourinary tract infection (GUTI), volume depletion, nocturia (>3 times/night), ketoacidosis and hypersensitivity reaction. 3 | RESULTS
| Ethics

| Study participants, flow and clinical characteristics
Of the 312 patients who were eligible for this study, 44 were excluded, resulting in 268 patients entering the study ( Figure S1 in File S1). Baseline characteristics of the patients are summarized in 
| Effectiveness outcomes
At Week 24, the HbA1c level was significantly reduced from baseline by 1.5 AE 1.2% (P < 0.001) and 1.1 AE 1.8% (P < 0.001) for the EMPA and INS groups, respectively. Interestingly, the difference in reduction of HbA1c was also significant (P = 0.004) between the EMPA and INS groups ( Figure 1A ). Moreover, the FPG level was significantly decreased from baseline to Week 24 (P < 0.001) in both the EMPA Of all measured values (Table 1) , the sensitivity analysis for fully adjusted effectiveness outcome measures resulted in a significant difference in only HbA1c, FPG, SBP and Wt after adjusting for multivariable covariates (ie, age, duration of diabetes, coronary heart disease, use of medications such as statins, ACEi or ARB, SBP, Wt, HbA1c, TC and spot urine albumin-to-creatinine ratio at baseline).
| Safety and tolerability
The overall incidence of treatment-related AEs is shown in Table S2 in File S1. In total, 21.1% and 27.0% of participants experienced one or more AEs in the EMPA and INS groups, respectively. AEs leading to treatment discontinuation were reported for nine patients, three with EMPA.
In terms of adverse events, there was a total of 47 hypoglycaemic events and there were considerably fewer in the EMPA group As a limitation of the open-label study design, the baseline Wt of EMPA patients was slightly, but not significantly, higher compared to INS patients. Insulin treatment seemed to be strongly recommended for the leaner patients, but not as strongly recommended for the more obese T2D patients. However, the effectiveness and safety endpoints did not change after re-analysing the data, adjusting for variable differences such as body weight, duration of diabetes, existing coronary heart disease and concomitant medication at baseline. With these limitations in mind, it is necessary that larger prospective studies will be undertaken and will match body weights in both groups to confirm the impact of EMPA compared to other antidiabetic drugs.
In conclusion, this study demonstrated that a treatment regimen consisting of four different OADs, including empagliflozin, can be an effective and safe therapeutic strategy for T2D patients who have inadequate glucose control while taking three other OADs.
